Cure My Disease

Don't miss your cure!

 Log in / Sign up

Massive ICU study aims to slash deadly catheter infections

NCT ID NCT06085690

Disease control Sponsor: Fudan University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a quality improvement program called 'ICU-NO CRBSI' to prevent catheter-related bloodstream infections in intensive care units. Over 8,000 patients across multiple hospitals in China will receive either standard care or an enhanced evidence-based infection prevention plan. The goal is to see if the program reduces infection rates and improves compliance with best practices.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
evidence-based intervention plan for preventing CRBSI in ICU patients
What this could lead to
If successful, this could establish a proven method to reduce dangerous bloodstream infections in ICUs, improving patient safety and lowering healthcare costs.
What could go wrong
This is an observational quality improvement study, not a controlled trial, so results may be influenced by other factors. The intervention is behavioral, not a drug, so its impact may vary across hospitals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 8,050 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2023

Expected to finish

Dec 2025

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ICU stay over 48 hours * CVC was placed for more than 24 hours Exclusion Criteria: * Pregnant patients * Patients with a history of CRBSI infection * Patients with central venous catheterization were brought in from other hospitals

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Central line infection are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Central line infection Central venous catheter associated bloodstream infection Central venous catheter related bloodstream infection Clabsi - central line associated bloodstream infection Crbsi - catheter related bloodstream infection Evidence-based nursing practice Quality improvement

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • ZhongShan Hospital Affilicated to Fudan University

    RECRUITING

    Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.